GlassScriptPhysician profile
Samantha E Barry
NPI 1396297495
$2,961.85
in general payments reported to CMS, 2019-2025
42 companies · $969 in 2025
The $969 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $444 · 2022: $616 · 2023: $279 · 2024: $654 · 2025: $969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,901.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $482.40 | 2021-2025 | |
| Corium, LLC | $202.66 | 2022-2024 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $200.79 | 2022-2025 | |
| Novo Nordisk INC | $195.44 | 2021-2025 | Wegovy |
| Janssen Biotech, INC. | $178.27 | 2025 | Tremfya |
| Lilly USA, LLC | $136.64 | 2021-2024 | Mounjaro |
| Seqirus USA INC | $114.80 | 2024 | Flucelvax, Fluad |
| Janssen Pharmaceuticals, INC | $109.96 | 2022-2024 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $103.54 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $87.96 | 2021-2025 | Entyvio, Eohilia |
| Pfizer INC. | $83.38 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $64.31 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $62.47 | 2022-2025 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $61.04 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $60.12 | 2021-2025 | Airsupra |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Barry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.